Döme Balázs, Magyar Melinda
Országos Korányi TBC és Pulmonológiai Intézet IV. Tüdogyógyászati Osztály 1529 Budapest Piheno u. 1. Országos Korányi TBC és Pulmonológiai Intézet Tumorbiológiai Osztály Budapest.
Magy Onkol. 2008 Sep;52(3):247-59. doi: 10.1556/MOnkol.52.2008.3.2.
Despite developments in conventional (chemo)radiotherapy and surgery, survival of non-small cell lung cancer (NSCLC) patients remains poor. Treatments with targeted molecular drugs offer novel therapeutic strategies. Bevacizumab, a recombinant anti-vascular endothelial growth factor (VEGF) antibody, is the antiangiogenic drug at the most advanced stage of development in the therapy of NSCLC. However, a number of questions and future challenges relating to the use of bevacizumab in NSCLC remain. Furthermore, novel agents targeting the pre-existing NSCLC vasculature (i.e. vascular disrupting agents, VDAs) or multiple tyrosine kinase inhibitors have emerged as unique drug classes delivering promising results in several preclinical and clinical studies. Herein, we review the most recent data using these novel targeted agents either alone or in combination with chemotherapy in NSCLC.
尽管传统（化疗）放疗和手术取得了进展，但非小细胞肺癌（NSCLC）患者的生存率仍然很低。靶向分子药物治疗提供了新的治疗策略。贝伐单抗是一种重组抗血管内皮生长因子（VEGF）抗体，是NSCLC治疗中处于最先进研发阶段的抗血管生成药物。然而，与贝伐单抗在NSCLC中的应用相关的一些问题和未来挑战仍然存在。此外，靶向已存在的NSCLC血管系统的新型药物（即血管破坏剂，VDAs）或多种酪氨酸激酶抑制剂已作为独特的药物类别出现，在多项临床前和临床研究中取得了有前景的结果。在此，我们综述了这些新型靶向药物单独或与化疗联合用于NSCLC的最新数据。
